\-\ Texto\\:\\ \ \(0\)\
\-\ renal\\ chromophobe\\ carcinoma\\ eosinophile\\ type\\ that\\ perforates\\ renal\\ capsule\\ and\\ infiltrates\\ perirenal\\ fat\\ tissue\ \(0\)\
\-\ treated\\ with\\ left\\ radical\\ nephrectomy\ \(0\)\
\-\ \\â\\€\\¢\\ scout\\ abdominal\\ scan\\ from\\ a\\ comuter\\ tomography\\ \\ demonstrates\\ a\\ radio\\-opaque\\ lobular\\ mass\\ \\ projected\\ in\\ the\\ left\\ renal\\ fossa\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ mdct\\ shows\\ a\\ heterogeneous\\ mass\\ arising\\ from\\ the\\ left\\ kidney\ \(0\)\
\-\ \\â\\€\\¢\\ there\\ is\\ irregular\\ enhancement\\ after\\ iv\\ contrast\ \(0\)\
\-\ chromophobe\\ renal\\ cell\\ carcinoma\\,\\ eosinophile\\ type\\,\\ that\\ perforates\\ renal\\ capsule\\ and\\ infiltrates\\ perirenal\\ fat\\ tissue\ \(0\)\
\-\ \\â\\€\\¢\\ renal\\ cell\\ carcinoma\ \(1\)\
\-\ \\*\\ oncocytoma\ \(0\)\
\-\ \\â\\€\\¢\\ transitional\\ cell\\ carcinoma\ \(0\)\
\-\ 40\\ y\\.o\\.\\ woman\\ with\\ evolution\\ over\\ one\\ month\\ or\\ lower\\ urinary\\ tract\\ symptoms\\,\\ left\\ renal\\ pain\\,\\ hematuria\\,\\ and\\ no\\ improvement\\ with\\ treatment\\.\ \(1\)\
\-\ renal\\ cell\\ carcinoma\\:\ \(0\)\
\-\ incidence\\ 80\\-90\\%\\ of\\ all\\ renal\\ malignant\\ primaries\\ in\\ adults\\.\ \(0\)\
\-\ arises\\ from\\ proximal\\ tubular\\ cells\\;\\ 30\\%\\ found\\ incidentally\\ with\\ imaging\\.\ \(0\)\
\-\ tumor\\ growth\\ pattern\\:\\ papillary\\ \\(best\\ prognosis\\)\\;\\ trabecular\\/tubular\\/cystic\\/solid\\ \\(poorer\\ prognosis\\)\\.\\ predisposing\\ factors\\:\\ tobacco\\,\\ von\\ hippel\\-lindau\\ disease\\,\\ hemodialysis\\,\\ acquired\\ cystic\\ disease\\ of\\ uremia\\.\ \(0\)\
\-\ the\\ most\\ common\\ sites\\ of\\ metastases\\ are\\ the\\ lung\\ \\(55\\%\\)\\,\\ lymph\\ nodes\\,\\ liver\\,\\ bone\\,\\ adrenals\\,\\ contralateral\\ kidney\\,\\ brain\\,\\ heart\\,\\ spleen\\.\\ it\\?s\\ important\\ to\\ know\\ that\\ 28\\%\\ of\\ patients\\ have\\ clinically\\ apparent\\ multiple\\ distant\\ metastases\\ at\\ presentation\\!\\ \ \(0\)\
\-\ radiology\\ findings\\ in\\ ct\\:\\ mostly\\ hterogeneous\\ enhancement\\ \\(due\\ to\\ cystic\\ areas\\ or\\ necrosis\\)\\,\\ subcapsular\\/perinephric\\ hemorrhage\\.\\ mri\\ best\\ modality\\ to\\ assess\\ stage\\ iii\\+iv\\ disease\\:\\ low\\ to\\ medium\\ signal\\ intensity\\ on\\ t1wi\\;\\ hyperintense\\ areas\\ are\\ usually\\ due\\ to\\ hemorrhage\\.\\ heterogeneous\\ signal\\ intensity\\ on\\ t2wi\\.\ \(0\)\
\-\ staging\\:\ \(0\)\
\-\ \\ \\ \\ \\ i\\:\\ confined\\ to\\ within\\ renal\\ capsule\ \(0\)\
\-\ \\ \\ \\ ii\\:\\ extension\\ into\\ perinephric\\ fat\\ but\\ confined\\ to\\ gerota\\ fascia\ \(0\)\
\-\ \\ \\ iiia\\:\\ extension\\ into\\ renal\\ vein\\ or\\ ivc\ \(0\)\
\-\ \\ iiib\\:\\ positive\\ lymph\\ nodes\ \(0\)\
\-\ \\ iiic\\:\\ extension\\ into\\ renal\\ vein\\ \\+\\ lymph\\ nodes\ \(0\)\
\-\ \\ iva\\:\\ extensio\\ into\\ adjacent\\ organs\\(\\ other\\ than\\ ipsilateral\\ adrenal\\)\ \(0\)\
\-\ \\ ivb\\:\\ distant\\ metastases\ \(0\)\
\-\ treatment\\ and\\ prognosis\\:\\ recurrence\\ in\\ 11\\%\\ after\\ 10\\ years\\.\\ radical\\ nephrectomy\\ has\\ a\\ 2\\-5\\%\\ operative\\ mortality\\.\\ tumor\\ stage\\ and\\ histological\\ grade\\ are\\ the\\ most\\ important\\ prognosticators\\!\ \(0\)\
\-\ chromophobe\\ carcinoma\\ of\\ kidney\\:\ \(0\)\
\-\ a\\ distinct\\ type\\ of\\ renal\\ cell\\ carcinoma\ \(0\)\
\-\ 5\\%\\ all\ \(0\)\
\-\ males\\=\\ females\\ in\\ contradistinction\\ to\\ classic\\ rcc\\ where\\ male\\ 2\\-3\\:1\\ females\ \(0\)\
\-\ unlike\\ other\\ renal\\ cell\\ carcinomas\\ can\\ be\\ hypovascular\\ on\\ imaging\ \(0\)\
\-\ birt\\-hogg\\-dube\\ syndrome\\ a\\ risk\\ factor\\ for\\ chromophobe\\ renal\\ cell\\ carcinoma\\ and\\ these\\ patients\\ need\\ to\\ be\\ screened\ \(0\)\
\-\ can\\ look\\ identical\\ to\\ oncocytoma\\,\\ and\\ in\\ case\\ reports\\ has\\ coexisted\\ with\\ this\\.\ \(0\)\
\-\ http\\:\\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/entrez\\/query\\.fcgi\\?cmd\\=search\\&db\\=pubmed\\&term\\=renal\\+chromophobe\\+carcinoma\\&tool\\=querysuggestion\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.4241781160908278\ \(0\)\
\-\ chromophobe\\:\\ 0\\.34041390811541894\ \(0\)\
\-\ carcinoma\\:\\ 0\\.22918479721877558\ \(0\)\
\-\ cell\\:\\ 0\\.1704742354329437\ \(0\)\
\-\ eosinophile\\:\\ 0\\.13616556324616758\ \(0\)\
\-\ perforates\\:\\ 0\\.1258194330176053\ \(0\)\
\-\ capsule\\:\\ 0\\.12496815591081795\ \(0\)\
\-\ prognosis\\:\\ 0\\.11239235008241241\ \(0\)\
\-\ perirenal\\:\\ 0\\.10942120457775649\ \(0\)\
\-\ nodes\\:\\ 0\\.10849607352117471\ \(0\)\
\-\ to\\:\\ 0\\.10643054828603316\ \(0\)\
\-\ metastases\\:\\ 0\\.10325260859689844\ \(0\)\
\-\ lymph\\:\\ 0\\.09931451047230187\ \(0\)\
\-\ oncocytoma\\:\\ 0\\.09677417339620203\ \(0\)\
\-\ perinephric\\:\\ 0\\.09525493326960452\ \(0\)\
\-\ radical\\:\\ 0\\.09432173499165358\ \(0\)\
\-\ infiltrates\\:\\ 0\\.0938761403861824\ \(0\)\
\-\ confined\\:\\ 0\\.09108176272865628\ \(0\)\
\-\ into\\:\\ 0\\.09052334691051038\ \(0\)\
\-\ extension\\:\\ 0\\.09040898903874693\ \(0\)\
\-\ kidney\\:\\ 0\\.08972633048191964\ \(0\)\
\-\ distant\\:\\ 0\\.08904319384915282\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.08697087792662116\ \(0\)\
\-\ type\\:\\ 0\\.08567789123684659\ \(0\)\
\-\ females\\:\\ 0\\.08564910239788555\ \(0\)\
\-\ fat\\:\\ 0\\.07944826561442901\ \(0\)\
\-\ cystic\\:\\ 0\\.07692000257739169\ \(0\)\
\-\ tubular\\:\\ 0\\.07397262322807562\ \(0\)\
\-\ important\\:\\ 0\\.07212483226804188\ \(0\)\
\-\ best\\:\\ 0\\.06851057460119343\ \(0\)\
\-\ comuter\\:\\ 0\\.06808278162308379\ \(0\)\
\-\ hterogeneous\\:\\ 0\\.06808278162308379\ \(0\)\
\-\ extensio\\:\\ 0\\.06808278162308379\ \(0\)\
\-\ prognosticators\\:\\ 0\\.06808278162308379\ \(0\)\
\-\ coexisted\\:\\ 0\\.06808278162308379\ \(0\)\
\-\ stage\\:\\ 0\\.06780526335698686\ \(0\)\
\-\ in\\:\\ 0\\.06354401840867673\ \(0\)\
\-\ iiic\\:\\ 0\\.06290971650880264\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.0616261319468234\ \(0\)\
\-\ and\\:\\ 0\\.061579679224887926\ \(0\)\
\-\ projected\\:\\ 0\\.06124436151183385\ \(0\)\
\-\ vein\\:\\ 0\\.06103098424379689\ \(0\)\
\-\ iv\\:\\ 0\\.06083776069408673\ \(0\)\
\-\ intensity\\:\\ 0\\.06045865940803199\ \(0\)\
\-\ primaries\\:\\ 0\\.05988366740315938\ \(0\)\
\-\ poorer\\:\\ 0\\.05988366740315938\ \(0\)\
\-\ uremia\\:\\ 0\\.05988366740315938\ \(0\)\
\-\ adrenals\\:\\ 0\\.05988366740315938\ \(0\)\
\-\ iva\\:\\ 0\\.05988366740315938\ \(0\)\
\-\ ivb\\:\\ 0\\.05988366740315938\ \(0\)\
\-\ iiia\\:\\ 0\\.05873321692666329\ \(0\)\
\-\ contradistinction\\:\\ 0\\.05873321692666329\ \(0\)\
\-\ left\\:\\ 0\\.05808970645624925\ \(0\)\
\-\ areas\\:\\ 0\\.05780762313917727\ \(0\)\
\-\ mdct\\:\\ 0\\.05773665139452151\ \(0\)\
\-\ hypovascular\\:\\ 0\\.05773665139452151\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.05700678606376876\ \(0\)\
\-\ iiib\\:\\ 0\\.056857618297516115\ \(0\)\
\-\ screened\\:\\ 0\\.056857618297516115\ \(0\)\
\-\ gerota\\:\\ 0\\.05607129639755271\ \(0\)\
\-\ that\\:\\ 0\\.05542467545676613\ \(0\)\
\-\ hemodialysis\\:\\ 0\\.05411323112394892\ \(0\)\
\-\ disease\\:\\ 0\\.05361133707042806\ \(0\)\
\-\ predisposing\\:\\ 0\\.05168455318323498\ \(0\)\
\-\ medium\\:\\ 0\\.05128104110957489\ \(0\)\
\-\ from\\:\\ 0\\.050724040460240115\ \(0\)\
\-\ all\\:\\ 0\\.05068485401523462\ \(0\)\
\-\ identical\\:\\ 0\\.05053410270673889\ \(0\)\
\-\ rcc\\:\\ 0\\.05018691660147006\ \(0\)\
\-\ of\\:\\ 0\\.04998756207972177\ \(0\)\
\-\ evolution\\:\\ 0\\.04985516619019705\ \(0\)\
\-\ know\\:\\ 0\\.04953753717459711\ \(0\)\
\-\ fascia\\:\\ 0\\.04953753717459711\ \(0\)\
\-\ enhancement\\:\\ 0\\.04900804175499136\ \(0\)\
\-\ due\\:\\ 0\\.04894300326092087\ \(0\)\
\-\ are\\:\\ 0\\.048463043954345524\ \(0\)\
\-\ signal\\:\\ 0\\.04826634073500747\ \(0\)\
\-\ patients\\:\\ 0\\.047898779626124\ \(0\)\
\-\ scout\\:\\ 0\\.04762746663480226\ \(0\)\
\-\ carcinomas\\:\\ 0\\.04762746663480226\ \(0\)\
\-\ unlike\\:\\ 0\\.04739052116595924\ \(0\)\
\-\ von\\:\\ 0\\.04716086749582679\ \(0\)\
\-\ histological\\:\\ 0\\.0469380701930912\ \(0\)\
\-\ t1wi\\:\\ 0\\.046511488068953846\ \(0\)\
\-\ transitional\\:\\ 0\\.045914116904024506\ \(0\)\
\-\ arises\\:\\ 0\\.04554088136432814\ \(0\)\
\-\ t2wi\\:\\ 0\\.04554088136432814\ \(0\)\
\-\ tobacco\\:\\ 0\\.045185425833962206\ \(0\)\
\-\ distinct\\:\\ 0\\.045185425833962206\ \(0\)\
\-\ imaging\\:\\ 0\\.04474663556660287\ \(0\)\
\-\ can\\:\\ 0\\.044681455066635976\ \(0\)\
\-\ tissue\\:\\ 0\\.044665204318407856\ \(0\)\
\-\ tumor\\:\\ 0\\.04453583136744436\ \(0\)\
\-\ mostly\\:\\ 0\\.04452159692457641\ \(0\)\
\-\ or\\:\\ 0\\.04443070022799634\ \(0\)\
\-\ most\\:\\ 0\\.04431209232727197\ \(0\)\
\-\ other\\:\\ 0\\.044217221388568304\ \(0\)\
\-\ ipsilateral\\:\\ 0\\.04405981117202164\ \(0\)\
\-\ organs\\:\\ 0\\.04391202108744793\ \(0\)\
\-\ staging\\:\\ 0\\.04348543896331058\ \(0\)\
\-\ lobular\\:\\ 0\\.04321402158381988\ \(0\)\
\-\ look\\:\\ 0\\.042824551198942774\ \(0\)\
\-\ contralateral\\:\\ 0\\.04257575631445377\ \(0\)\
\-\ the\\:\\ 0\\.0424738354430967\ \(0\)\
\-\ modality\\:\\ 0\\.042101745898417836\ \(0\)\
\-\ mortality\\:\\ 0\\.041875572366089915\ \(0\)\
\-\ with\\:\\ 0\\.04168119136346086\ \(0\)\
\-\ sites\\:\\ 0\\.04154866658685108\ \(0\)\
\-\ spleen\\:\\ 0\\.041442804451804344\ \(0\)\
\-\ ivc\\:\\ 0\\.04133842295467271\ \(0\)\
\-\ after\\:\\ 0\\.04130528748898362\ \(0\)\
\-\ tomography\\:\\ 0\\.04123548124830208\ \(0\)\
\-\ acquired\\:\\ 0\\.04103376206637837\ \(0\)\
\-\ treatment\\:\\ 0\\.04055913270865051\ \(0\)\
\-\ factor\\:\\ 0\\.039926080505705314\ \(0\)\
\-\ adults\\:\\ 0\\.039756456036248555\ \(0\)\
\-\ papillary\\:\\ 0\\.03967306795770391\ \(0\)\
\-\ adrenal\\:\\ 0\\.039428352414877854\ \(0\)\
\-\ assess\\:\\ 0\\.039348531810295274\ \(0\)\
\-\ need\\:\\ 0\\.03919140694603484\ \(0\)\
\-\ has\\:\\ 0\\.03889180424558002\ \(0\)\
\-\ on\\:\\ 0\\.0385729259954718\ \(0\)\
\-\ hematuria\\:\\ 0\\.03765148608466164\ \(0\)\
\-\ improvement\\:\\ 0\\.03716192337253335\ \(0\)\
\-\ urinary\\:\\ 0\\.036814737267264516\ \(0\)\
\-\ incidence\\:\\ 0\\.036647018852060634\ \(0\)\
\-\ 55\\:\\ 0\\.036591939964528926\ \(0\)\
\-\ incidentally\\:\\ 0\\.036269739337523206\ \(0\)\
\-\ factors\\:\\ 0\\.036011472896037254\ \(0\)\
\-\ operative\\:\\ 0\\.03571290686752353\ \(0\)\
\-\ tract\\:\\ 0\\.035664286790768426\ \(0\)\
\-\ apparent\\:\\ 0\\.035615981409271184\ \(0\)\
\-\ clinically\\:\\ 0\\.03537903594042816\ \(0\)\
\-\ 28\\:\\ 0\\.03533253637949541\ \(0\)\
\-\ recurrence\\:\\ 0\\.03514938227029572\ \(0\)\
\-\ growth\\:\\ 0\\.03510428753861635\ \(0\)\
\-\ be\\:\\ 0\\.03453996624987999\ \(0\)\
\-\ radiology\\:\\ 0\\.034096490769762684\ \(0\)\
\-\ hyperintense\\:\\ 0\\.033864456887399384\ \(0\)\
\-\ arising\\:\\ 0\\.03382647637089208\ \(0\)\
\-\ ii\\:\\ 0\\.03356589085888566\ \(0\)\
\-\ where\\:\\ 0\\.03345693775034825\ \(0\)\
\-\ fossa\\:\\ 0\\.03342097066682437\ \(0\)\
\-\ reports\\:\\ 0\\.03310483682410063\ \(0\)\
\-\ irregular\\:\\ 0\\.032867891355257604\ \(0\)\
\-\ cells\\:\\ 0\\.03280155175945966\ \(0\)\
\-\ necrosis\\:\\ 0\\.03254193756981897\ \(0\)\
\-\ mass\\:\\ 0\\.03252315814709384\ \(0\)\
\-\ 11\\:\\ 0\\.03187132582311583\ \(0\)\
\-\ classic\\:\\ 0\\.03184222966389742\ \(0\)\
\-\ pattern\\:\\ 0\\.03178437545645371\ \(0\)\
\-\ http\\:\\ 0\\.031473953737779496\ \(0\)\
\-\ 40\\:\\ 0\\.03130992174171037\ \(0\)\
\-\ grade\\:\\ 0\\.030613370972511128\ \(0\)\
\-\ risk\\:\\ 0\\.030418880347043365\ \(0\)\
\-\ malignant\\:\\ 0\\.03034723350508117\ \(0\)\
\-\ heart\\:\\ 0\\.029601426998112437\ \(0\)\
\-\ liver\\:\\ 0\\.02936851530401129\ \(0\)\
\-\ presentation\\:\\ 0\\.029306235481784872\ \(0\)\
\-\ 30\\:\\ 0\\.029042205171477473\ \(0\)\
\-\ positive\\:\\ 0\\.028053126503752135\ \(0\)\
\-\ adjacent\\:\\ 0\\.02759553667824935\ \(0\)\
\-\ found\\:\\ 0\\.02754638289758257\ \(0\)\
\-\ usually\\:\\ 0\\.026800999966904458\ \(0\)\
\-\ proximal\\:\\ 0\\.026596916595403183\ \(0\)\
\-\ brain\\:\\ 0\\.026539617616160735\ \(0\)\
\-\ treated\\:\\ 0\\.026511132255676736\ \(0\)\
\-\ years\\:\\ 0\\.026096405821699867\ \(0\)\
\-\ month\\:\\ 0\\.02589737654983828\ \(0\)\
\-\ lung\\:\\ 0\\.02589737654983828\ \(0\)\
\-\ syndrome\\:\\ 0\\.025665342667474982\ \(0\)\
\-\ scan\\:\\ 0\\.025257823530423835\ \(0\)\
\-\ shows\\:\\ 0\\.024986406150933144\ \(0\)\
\-\ 10\\:\\ 0\\.024894267259814255\ \(0\)\
\-\ low\\:\\ 0\\.0244283618838313\ \(0\)\
\-\ one\\:\\ 0\\.024374785520316394\ \(0\)\
\-\ common\\:\\ 0\\.024143514312869357\ \(0\)\
\-\ than\\:\\ 0\\.024133170367503735\ \(0\)\
\-\ these\\:\\ 0\\.024040714403969623\ \(0\)\
\-\ over\\:\\ 0\\.023672211603191426\ \(0\)\
\-\ symptoms\\:\\ 0\\.02329328984959212\ \(0\)\
\-\ abdominal\\:\\ 0\\.023284058982136327\ \(0\)\
\-\ bone\\:\\ 0\\.023228912262845455\ \(0\)\
\-\ woman\\:\\ 0\\.022171925223640258\ \(0\)\
\-\ mri\\:\\ 0\\.02185297166186831\ \(0\)\
\-\ it\\:\\ 0\\.021792295267596615\ \(0\)\
\-\ lower\\:\\ 0\\.02175462151073367\ \(0\)\
\-\ demonstrates\\:\\ 0\\.021387988099343915\ \(0\)\
\-\ case\\:\\ 0\\.021387988099343915\ \(0\)\
\-\ have\\:\\ 0\\.021267325802393336\ \(0\)\
\-\ but\\:\\ 0\\.021052194387352084\ \(0\)\
\-\ findings\\:\\ 0\\.021011262902376582\ \(0\)\
\-\ multiple\\:\\ 0\\.020823162620922892\ \(0\)\
\-\ contrast\\:\\ 0\\.02068513467689945\ \(0\)\
\-\ within\\:\\ 0\\.0196076055020958\ \(0\)\
\-\ male\\:\\ 0\\.018954938651848673\ \(0\)\
\-\ there\\:\\ 0\\.01693948704055756\ \(0\)\
\-\ ct\\:\\ 0\\.0162077709429375\ \(0\)\
\-\ at\\:\\ 0\\.016080192530531695\ \(0\)\
\-\ pain\\:\\ 0\\.015234026481113355\ \(0\)\
\-\ this\\:\\ 0\\.014628696159944457\ \(0\)\
\-\ no\\:\\ 0\\.013844110079360102\ \(0\)\
\-\ for\\:\\ 0\\.012903414330784005\ \(0\)\
\-\ is\\:\\ 0\\.011658783100631646\ \(0\)\
